NovaBay to Hold Conference Call to Review Aganocide Data Presented at the Infectious Diseases Society of America Meeting

By October 28, 2009

NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) will hold a webcast conference call on October 30, 2009 to review preclinical data from a study of Aganocide® product candidates NVC-422 and NVC-612 in a model of onychomycosis, commonly termed nail fungus. The study data will be presented on October 31, 2009 in Philadelphia, PA at the 47th Annual Meeting of the Infectious Diseases Society of America. During the conference call, Dr. Ron Najafi, chairman and chief executive officer and Dr. Behzad Khosrovi, senior vice president of product development, both of NovaBay, will also provide a brief update of the Company’s clinical progress and corporate development efforts.

Conference call information:
Date/time of live call: Friday October 30, 2009, 10:00 AM eastern time
US/Canada dial-in: (877) 862-4241 / international dial-in: (281) 312-0948
US/Canada replay: (800) 642-1687 / international replay: (706) 645-9291
Passcode for live and archived conference call is 37797881

For the live and archived webcast, please visit the Investor Events page on the NovaBay website at www.novabaypharma.com The webcast will be archived for 90 days and the telephone replay for seven days.

The poster presented at the Annual Meeting of the Infectious Diseases Society of America is titled “In Vitro
Evaluation of Stable Derivatives of the Chlorotaurines on Infected Human Nail Model as Potent Antifungal Agents for the Treatment of Onychomycosis” and may be found on the NovaBay website on the NovaBay Publications
page under Technology on or about October 31, 2009.

About NovaBay

NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay™ and Aganocide® are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit: www.novabaypharma.com.

For information, contact:

Investors:
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson  
Chief Financial Officer
510-899-8809
Contact Thomas Paulson

Media Relations:
Aimee Corso, 503-855-4502
acorso@wcpglobal.com

TOP